Systemic lupus erythematosus (SLE) is a prototypic autoimmune disease that is characterized by systemic chronic inflammation that can affect multiple major organ systems. A major contributor to morbidity and mortality among patients with SLE is renal involvement, known as lupus nephritis (LN). Treatment of systemic lupus erythematosus is guided by the individual patient’s manifestations. Fever, rash, musculoskeletal manifestations, and serositis generally respond to treatment with hydroxychloroquine, nonsteroidal anti-inflammatory drugs (NSAIDS), and steroids in low to moderate doses, as necessary, for acute flares. Medications such as methotrexate may be useful in chronic lupus arthritis, and azathioprine and mycophenolate have been widely used in lupus of moderate severity. The treatment options for LN include acetaminophen or NSAIDs. Acetaminophen and NSAIDS are often enough to reduce symptoms, but sometimes are prescribed in combination with antimalarial drugs such as hydroxychloroquine (Plaquenil). Low-dose corticosteroids such as prednisone and/or corticosteroid creams or ointments. Central nervous system involvement and renal disease constitute more serious disease and often require high-dose steroids and other immunosuppressive agents, such as azathioprine, belimumab, cyclophosphamide, methotrexate, or mycophenolate mofetil. The LUMINA (Lupus in Minorities: Nature versus Nurture) study and other trials have offered evidence of a decrease in flares and prolonged life in patients given hydroxychloroquine, making it the cornerstone of SLE management.
The global systemic lupus erythematosus and lupus nephritis drugs market segmentation is based on drug class (antimalarials, biologics, immunosuppressives, steroids).
The global systemic lupus erythematosus and lupus nephritis drugs market research report provides market size (Revenue US$ Million 2014 to 2021), market share analysis, growth trends and forecast (CAGR%, 2017 to 2021). The global systemic lupus erythematosus and lupus nephritis drugs market research report is further segmented by geography into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World. In addition, the global systemic lupus erythematosus and lupus nephritis drugs market report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.
Major players operating in the global systemic lupus erythematosus and lupus nephritis drugs market and profiled in this report include Active Biotech, Anthera, Biogen Idec, Bristol-Myers Squibb, Eli Lilly, Galapagos NV, Genentech (Roche), GlaxoSmithKline, Immunomedics, ImmuPharma, Invion, Johnson & Johnson, MedImmune, Merck Serono, Pfizer, SuppreMol, Teva Pharmaceutical Industries Ltd., and UCB (Union Chimique Belge).